KRAS and non-small cell lung carcinoma: Demonstration of a clear clinical benefit in a KRAS mutation-positive NSCLC population leading to drug approval would drive the need to identify relevant KRAS mutations in NSCLC patients at diagnosis, in addition to EGFR and ALK aberrations, to inform treatment decisions.